Target type: biologicalprocess
Any process that stops, prevents, or reduces the frequency, rate or extent of RNA splicing. [GOC:mah]
Negative regulation of RNA splicing is a fundamental biological process that controls the precise removal of non-coding introns from pre-messenger RNA (pre-mRNA) to produce mature messenger RNA (mRNA). This process is essential for proper gene expression and protein synthesis.
Here's a detailed breakdown of the biological process:
**1. Transcription:** The first step involves the transcription of DNA into pre-mRNA. Pre-mRNA contains both coding exons and non-coding introns.
**2. Splicing Factors and Regulatory Proteins:** Negative regulation of splicing involves various proteins and factors that bind to specific sequences within the pre-mRNA. These factors can:
- **Block Spliceosome Assembly:** They can directly interfere with the formation of the spliceosome, a complex of proteins and small nuclear RNAs (snRNAs) responsible for removing introns.
- **Induce Alternative Splicing:** They can alter the splicing pattern, leading to the inclusion or exclusion of specific exons, thereby producing different protein isoforms.
**3. Inhibition of Spliceosome Activity:** Some regulatory proteins can directly inhibit the enzymatic activity of the spliceosome, preventing it from correctly recognizing and removing introns.
**4. Competitive Binding:** Negative regulators can compete with splicing factors for binding sites within the pre-mRNA, effectively blocking their access and inhibiting splicing.
**5. Recruitment of Repressor Proteins:** Some regulatory proteins can recruit other repressor proteins to the pre-mRNA, further enhancing the inhibitory effect on splicing.
**6. Chromatin Modifications:** Changes in chromatin structure, such as histone modifications, can influence the accessibility of pre-mRNA to splicing machinery, potentially leading to negative regulation of splicing.
**7. RNA Secondary Structures:** Formation of specific RNA secondary structures within the pre-mRNA can also block splicing by interfering with the binding of spliceosome components.
**8. MicroRNAs (miRNAs):** miRNAs can regulate splicing by targeting specific sequences within pre-mRNAs, leading to their degradation or inhibition of translation.
**Consequences of Negative Regulation of RNA Splicing:**
- **Control of Gene Expression:** Negative regulation of splicing provides a fine-tuning mechanism for gene expression by controlling the amount and type of protein produced.
- **Generation of Protein Isoforms:** Alternative splicing, often regulated negatively, leads to the production of different protein isoforms with distinct functions.
- **Cellular Differentiation and Development:** Splicing regulation plays a critical role in cellular differentiation and development by influencing the expression of specific genes and proteins.
- **Disease Pathogenesis:** Dysregulation of splicing can contribute to various diseases, including cancer, neurological disorders, and genetic diseases.
In summary, negative regulation of RNA splicing is a complex and highly regulated process that is essential for maintaining proper gene expression and cellular function. It involves a multitude of factors and mechanisms that act together to control the precise removal of introns from pre-mRNA, ensuring the production of functional proteins.'
"
Protein | Definition | Taxonomy |
---|---|---|
40S ribosomal protein S26 | A small ribosomal subunit protein eS26 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P62854] | Homo sapiens (human) |
40S ribosomal protein S13 | A eukaryotic-type small ribosomal subunit protein uS15 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P62277] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
gentamicin sulfate | |||
PF-06446846 | PF-06446846 : A triazolopyridine that is 3H-[1,2,3]triazolo[4,5-b]pyridine substituted by a 4-{(3-chloropyridin-2-yl)[(3R)-piperidin-3-yl]carbamoyl}phenyl group at position 3. It is a potent inhibitor of PCSK9. PF-06446846: inhibits translation of PCSK9 ;structure in first source | benzamides; monochloropyridine; piperidines; tertiary carboxamide; triazolopyridine | antilipemic drug; EC 3.4.21.61 (kexin) inhibitor |